Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Justin Penik gives his thoughts and observations from the Giants-Jets joint practice. 00:00 Giants vs jets Practice Recap ...

While Wall Street analysts remain cautious on Hims & Hers Health ($HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects ...

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

The Voya Small Company Fund underperformed its benchmark, the Russell 2000 Index (the Index) on a net asset value basis. Read ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...